Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Fastly Inc (FSLY) vs Smith & Nephew plc (SNN) Price & Performance

Fastly IncTrade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

Fastly Inc vs Smith & Nephew plc — how do they compare? Fastly Inc trades at $20.77 (market cap $3.13B), while Smith & Nephew plc trades at $31.22 (market cap $12.81B). The key difference: Smith & Nephew plc is far larger — about 4.1× Fastly Inc's market cap, and Smith & Nephew plc pays a 2.54% dividend while Fastly Inc pays none. Which is the better fit depends on your goals.

FSLYSNN
Market Cap
$3.13B$12.81B
Sector
TechnologyHealth
52-Week High
$33.50$38.70
52-Week Low
$6.36$28.73
Enterprise Value
$3.20B$15.58B
Dividend Yield
2.54%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Fastly Inc

Fastly (FSLY) trades at $20.90, up 4.34% today, showing strong momentum after three consecutive quarterly earnings beats. The stock maintains a bullish technical signal with positive moving averages and trades near key resistance at $21-$22. Revenue growth continues at 20% year-over-year, though the company remains unprofitable with a -15.79% net margin. Recent news highlights strategic partnerships in edge computing and AI infrastructure development.

Despite consistent revenue growth and improving margins, Fastly faces profitability challenges with negative ROE and cash flow volatility. Analyst consensus is mixed with 29% buy ratings but a $24.25 price target suggesting 16% upside. Key risks include competitive pressure from larger cloud providers and the company's ability to achieve sustainable profitability amid heavy infrastructure investments.

Smith & Nephew plc

Smith & Nephew (SNN) trades at $29.83, down 4.02% today, with a bearish technical signal. The company reported revenue of $5.81 billion in 2024, with net income of $412 million, showing improved profitability. Recent news highlights product launches in robotics and wound care, supported by a $500 million share buyback. Analyst consensus is mixed, with 27% buy ratings but 68% hold, reflecting cautious optimism amid earnings volatility.

Outlook is balanced: strong free cash flow and innovation in medical technology offer growth potential, but near-term risks include competitive pressures and debt levels. The stock's valuation at a P/E of 21.51 is reasonable if earnings growth sustains, yet technical weakness suggests caution. Investors should weigh solid fundamentals against market sentiment and execution risks.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Fastly Inc

Fastly operates a content delivery network, which is necessary for entities to provide faster and more reliable online content. Fastly's strategy differs from traditional CDNs, which focused on locating servers in as many locations as possible to store copies of files that consumers most use. Fastly has far fewer sites than traditional CDNs, but it houses servers in the most network-dense data centers. Instead of simply storing static content, it allows its customers to program on its platform, enabling edge computing and better service of the more dynamic content that was traditionally not well served by CDNs. Fastly gears its service to the largest, most sophisticated enterprises rather than small companies and generated about two thirds of its revenue in the United States in 2020.

Read more on FSLY

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN